Key facts
- It has raised $500K; the latest was Early Stage VC in Sep 2025.
- Notable investors include Y Combinator, Alumni Ventures, Rebel Fund, Multimodal Ventures, BoxOne Ventures — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Blank Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Blank Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Blank Bio
Developer of ribonucleic acid (RNA) analysis technology designed for mRNA design and transcript characterisation. The company's platform offers leverage of advanced machine learning and large-scale biological data to build foundation models that can predict, analyse, and optimise RNA sequences for therapeutic applications, enabling the biotechnology and pharmaceutical markets to enhance drug discovery processes, improve the efficiency of RNA-based drug development, and reduce the time and cost associated with bringing new therapies to market.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2025
- Employees
- 3
- Website
- blank.bio/
- Ownership
- Privately Held (backing)
Blank Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Blank Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Blank Bio in its N-PORT filings yet. We sweep new filings monthly.